Analyst Price Targets — HLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 10, 2025 9:40 am | Rashad Kawan | Morgan Stanley | $10.20 | $9.10 | TheFly | Haleon downgraded to Equal Weight from Overweight at Morgan Stanley |
| April 8, 2024 7:42 am | Rashad Kawan | Morgan Stanley | $9.15 | $8.29 | StreetInsider | Haleon Plc. (HLN) PT Lowered to $9.15 at Morgan Stanley |
Latest News for HLN
Haleon PLC Sponsored ADR (HLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Haleon PLC faces a familiar market dilemma after solid profit delivery was overshadowed by weaker than expected sales growth and cautious guidance. Fourth quarter organic growth of 2.1% disappointed, said Deutsche Bank, with misses in EMEA, Latin America and Asia Pacific, while North America was still down 1.0% like for like.
Haleon plc (HLN) Q4 2025 Earnings Call Prepared Remarks Transcript
Haleon plc (HLN) Q4 2025 Earnings Call Transcript
A weak cold and flu season and a cautious American consumer pushed organic growth to 3%, a full percentage point below the floor of what Haleon has promised investors Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.4% to 392.1p on Wednesday after the consumer health group reported full-year organic revenue growth of 3%, missing the 4-6% medium-term range it has set as its benchmark and leaving investors to weigh…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for HLN.
Senate Trading
No Senate trades found for HLN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.